Literature DB >> 19723551

The A3 adenosine receptor attenuates the calcium rise triggered by NMDA receptors in retinal ganglion cells.

Mei Zhang1, Huiling Hu, Xiulan Zhang, Wennan Lu, Jason Lim, Thor Eysteinsson, Kenneth A Jacobson, Alan M Laties, Claire H Mitchell.   

Abstract

The A(3) adenosine receptor is emerging as an important regulator of neuronal signaling, and in some situations receptor stimulation can limit excitability. As the NMDA receptor frequently contributes to neuronal excitability, this study examined whether A(3) receptor activation could alter the calcium rise accompanying NMDA receptor stimulation. Calcium levels were determined from fura-2 imaging of isolated rat retinal ganglion cells as these neurons possess both receptor types. Brief application of glutamate or NMDA led to repeatable and reversible elevations of intracellular calcium. The A(3) agonist Cl-IB-MECA reduced the response to both glutamate and NMDA. While adenosine mimicked the effect of Cl-IB-MECA, the A(3) receptor antagonist MRS 1191 impeded the block by adenosine, implicating a role for the A(3) receptor in response to the natural agonist. The A(1) receptor antagonist DPCPX provided additional inhibition, implying a contribution from both A(1) and A(3) adenosine receptors. The novel A(3) agonist MRS 3558 (1'S,2'R,3'S,4'R,5'S)-4-(2-chloro-6-(3-chlorobenzylamino)-9H-purin-9-yl)-2,3-dihydroxy-N-methylbicyclo [3.1.0] hexane-1-carboxamide and mixed A(1)/A(3) agonist MRS 3630 (1'S,2'R,3'S,4'R,5'S)-4-(2-chloro-6-(cyclopentylamino)-9H-purin-9-yl)-2,3-dihydroxy-N-methylbicyclo [3.1.0] hexane-1-carboxamide also inhibited the calcium rise induced by NMDA. Low levels of MRS 3558 were particularly effective, with an IC(50) of 400 pM. In all cases, A(3) receptor stimulation inhibited only 30-50% of the calcium rise. In summary, stimulation of the A(3) adenosine receptor by either endogenous or synthesized agonists can limit the calcium rise accompanying NMDA receptor activation. It remains to be determined if partial block of the calcium rise by A(3) agonists can modify downstream responses to NMDA receptor stimulation. 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19723551      PMCID: PMC2814940          DOI: 10.1016/j.neuint.2009.08.011

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  44 in total

1.  Are A3 adenosine receptors expressed in the brain?

Authors:  S A Rivkees; S Thevananther; H Hao
Journal:  Neuroreport       Date:  2000-04-07       Impact factor: 1.837

2.  Glial cell inhibition of neurons by release of ATP.

Authors:  Eric A Newman
Journal:  J Neurosci       Date:  2003-03-01       Impact factor: 6.167

3.  Signaling pathway from the human adenosine A(3) receptor expressed in Chinese hamster ovary cells to the extracellular signal-regulated kinase 1/2.

Authors:  Gunnar Schulte; Bertil B Fredholm
Journal:  Mol Pharmacol       Date:  2002-11       Impact factor: 4.436

4.  The influence of adenosine A3 receptor agonist: IB-MECA, on scopolamine- and MK-801-induced memory impairment.

Authors:  Andrzej Rubaj; Witold Zgodziński; Maria Sieklucka-Dziuba
Journal:  Behav Brain Res       Date:  2003-04-17       Impact factor: 3.332

5.  Right thing at a wrong time? Adenosine A3 receptors and cerebroprotection in stroke.

Authors:  D K Von Lubitz; K L Simpson; R C Lin
Journal:  Ann N Y Acad Sci       Date:  2001-06       Impact factor: 5.691

6.  Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells.

Authors:  B B Fredholm; E Irenius; B Kull; G Schulte
Journal:  Biochem Pharmacol       Date:  2001-02-15       Impact factor: 5.858

7.  Propagation of intercellular calcium waves in retinal astrocytes and Müller cells.

Authors:  E A Newman
Journal:  J Neurosci       Date:  2001-04-01       Impact factor: 6.167

8.  Brain adenosine receptors as targets for therapeutic intervention in neurodegenerative diseases.

Authors:  M P Abbracchio; F Cattabeni
Journal:  Ann N Y Acad Sci       Date:  1999       Impact factor: 5.691

9.  Adenosine inhibits calcium channel currents via A1 receptors on salamander retinal ganglion cells in a mini-slice preparation.

Authors:  Xiaolu Sun; Steven Barnes; William H Baldridge
Journal:  J Neurochem       Date:  2002-05       Impact factor: 5.372

Review 10.  International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors.

Authors:  B B Fredholm; A P IJzerman; K A Jacobson; K N Klotz; J Linden
Journal:  Pharmacol Rev       Date:  2001-12       Impact factor: 18.923

View more
  23 in total

Review 1.  Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions.

Authors:  Rebecca K Donegan; Raquel L Lieberman
Journal:  J Med Chem       Date:  2015-09-25       Impact factor: 7.446

2.  Inhibition of experimental auto-immune uveitis by the A3 adenosine receptor agonist CF101.

Authors:  Sara Bar-Yehuda; Dror Luger; Avivit Ochaion; Shira Cohen; Renana Patokaa; Galina Zozulya; Phyllis B Silver; Jose Maria Garcia Ruiz de Morales; Rachel R Caspi; Pnina Fishman
Journal:  Int J Mol Med       Date:  2011-07-19       Impact factor: 4.101

3.  Stimulation of the P2X7 receptor kills rat retinal ganglion cells in vivo.

Authors:  Huiling Hu; Wennan Lu; Mei Zhang; Xiulan Zhang; Arthur J Argall; Shaun Patel; Ga Eun Lee; Yong-Chul Kim; Kenneth A Jacobson; Alan M Laties; Claire H Mitchell
Journal:  Exp Eye Res       Date:  2010-07-01       Impact factor: 3.467

Review 4.  Ocular Purine Receptors as Drug Targets in the Eye.

Authors:  Kenneth A Jacobson; Mortimer M Civan
Journal:  J Ocul Pharmacol Ther       Date:  2016-08-30       Impact factor: 2.671

5.  Controlling murine and rat chronic pain through A3 adenosine receptor activation.

Authors:  Zhoumou Chen; Kali Janes; Collin Chen; Tim Doyle; Leesa Bryant; Dilip K Tosh; Kenneth A Jacobson; Daniela Salvemini
Journal:  FASEB J       Date:  2012-02-17       Impact factor: 5.191

6.  The P2X7 receptor links mechanical strain to cytokine IL-6 up-regulation and release in neurons and astrocytes.

Authors:  Wennan Lu; Farraj Albalawi; Jonathan M Beckel; Jason C Lim; Alan M Laties; Claire H Mitchell
Journal:  J Neurochem       Date:  2017-05       Impact factor: 5.372

7.  Rat, mouse, and primate models of chronic glaucoma show sustained elevation of extracellular ATP and altered purinergic signaling in the posterior eye.

Authors:  Wennan Lu; HuiLing Hu; Jean Sévigny; B'Ann T Gabelt; Paul L Kaufman; Elaine C Johnson; John C Morrison; Gulab S Zode; Val C Sheffield; Xiulan Zhang; Alan M Laties; Claire H Mitchell
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-05       Impact factor: 4.799

Review 8.  Purinergic signaling in the retina: From development to disease.

Authors:  Ana Lucia Marques Ventura; Alexandre Dos Santos-Rodrigues; Claire H Mitchell; Maria Paula Faillace
Journal:  Brain Res Bull       Date:  2018-11-17       Impact factor: 4.077

Review 9.  Identification of A3 adenosine receptor agonists as novel non-narcotic analgesics.

Authors:  K Janes; A M Symons-Liguori; K A Jacobson; D Salvemini
Journal:  Br J Pharmacol       Date:  2016-03-06       Impact factor: 8.739

10.  A3 adenosine receptor agonist prevents the development of paclitaxel-induced neuropathic pain by modulating spinal glial-restricted redox-dependent signaling pathways.

Authors:  Kali Janes; Emanuela Esposito; Timothy Doyle; Salvatore Cuzzocrea; Dillip K Tosh; Kenneth A Jacobson; Daniela Salvemini
Journal:  Pain       Date:  2014-09-19       Impact factor: 6.961

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.